71266-18-7Relevant academic research and scientific papers
NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
-
, (2009/10/31)
The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
Quinoxaline chemistry. Part 4. 2-(R)-anilinoquinoxalines as nonclassical antifolate agents. Synthesis, structure elucidation and evaluation of in vitro anticancer activity
Loriga,Fiore,Sanna,Paglietti
, p. 289 - 301 (2007/10/02)
Thirty-five quinoxalines bearing a substituted amiline group on position 2 and various substituents on positions 3, 6, 7 and 8 were prepared in order to evaluate in vitro anticancer activity. Structural elucidation of some isomeric quinoxalinones formed by ring closure of 4-substituted-1,2-diaminobenzenes with dicarbonyl compounds was achieved by comparison with one isomer coming from an unambiguous independent route. Preliminary in vitro screening at NCI showed that many compounds exhibited a moderate to strong growth inhibition activity on various cell lines between 10-5 and 10-4 molar concentrations.
